ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
17.896,50
-0,14%
S&P 500
5.041,19
0,45%
Dow Jones
38.067,89
0,43%
Euro vs US Dollar
1,07185
0,01%
Bitcoin
59.049,47
1,39%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Kanada
  5. TSX
  6. Eupraxia Pharmaceuticals Inc (EPRX)

  7. Eupraxia Pharmaceuticals Inc (EPRX) News

EPRX

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:TSX:EPRX
DatumZeitQuelleÜberschriftSymbolFirma
02/05/202413h00PR Newswire (US)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardTSX:EPRXEupraxia Pharmaceuticals Inc
02/05/202413h00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardTSX:EPRXEupraxia Pharmaceuticals Inc
11/04/202413h00PR Newswire (US)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024TSX:EPRXEupraxia Pharmaceuticals Inc
11/04/202413h00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024TSX:EPRXEupraxia Pharmaceuticals Inc
08/04/202413h00PR Newswire (Canada)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
08/04/202413h00PR Newswire (US)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
05/04/202413h00PR Newswire (US)Eupraxia Pharmaceuticals Begins Trading on Nasdaq TodayTSX:EPRXEupraxia Pharmaceuticals Inc
05/04/202413h00PR Newswire (Canada)Eupraxia Pharmaceuticals Begins Trading on Nasdaq TodayTSX:EPRXEupraxia Pharmaceuticals Inc
03/04/202423h00PR Newswire (Canada)Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
03/04/202423h00PR Newswire (US)Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
01/04/202423h01PR Newswire (Canada)Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
01/04/202423h01PR Newswire (US)Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
12/03/202414h41PR Newswire (Canada)L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
12/03/202414h39PR Newswire (Canada)Canadian Investment Regulatory Organization Trade Resumption - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
11/03/202421h06PR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
11/03/202421h04PR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
05/02/202423h00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
01/02/202413h00PR Newswire (Canada)Eupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IARTSX:EPRXEupraxia Pharmaceuticals Inc
30/01/202413h00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the KneeTSX:EPRXEupraxia Pharmaceuticals Inc
09/01/202400h44PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Filing of Preliminary MJDS Base Shelf ProspectusTSX:EPRXEupraxia Pharmaceuticals Inc
12/12/202313h00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Positive Clinical Data in EP-104GI RESOLVE TrialTSX:EPRXEupraxia Pharmaceuticals Inc
11/12/202313h00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Clinical and Corporate UpdateTSX:EPRXEupraxia Pharmaceuticals Inc
14/11/202323h01PR Newswire (Canada)Eupraxia Pharmaceuticals Reports Third Quarter 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
01/11/202312h00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present at the 2023 Annual Meeting of the American College of RheumatologyTSX:EPRXEupraxia Pharmaceuticals Inc
11/10/202313h00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Initiation of Second Cohort in Phase 1b/2a Clinical Trial in Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
11/09/202321h32PR Newswire (Canada)Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
07/09/202323h00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Change of AuditorTSX:EPRXEupraxia Pharmaceuticals Inc
06/09/202323h00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Presentation at PAINWeek 2023TSX:EPRXEupraxia Pharmaceuticals Inc
19/08/202301h20PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Closing of Non-Brokered Private Placement for Gross Proceeds of C$22,287,125TSX:EPRXEupraxia Pharmaceuticals Inc
11/08/202323h00PR Newswire (Canada)Eupraxia Pharmaceuticals Reports Second Quarter 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
 Showing the most relevant articles for your search:TSX:EPRX

Kürzlich von Ihnen besucht

NASDAQ
QQQ
Invesco QQQ Trust Series 1
AMEX
XLF
Financial Select Sector
TG
DBK
Deutsche Bank
NASDAQ
NVDA
NVIDIA
COIN
BTCUSD
Bitcoin
TG
ALV
Allianz
FX
EURGBP
Euro vs Sterling
AMEX
SPY
SPDR S&P 500
TG
TUI1
Tui
NYSE
MRK
Merck
NASDAQ
GOOGL
Alphabet
TG
DTE
Deutsche Telekom
CCOM
SILVER
SILVER
USOTC
RHHBY
Roche (QX)
USOTC
DTEGY
Deutsche Telekom (QX)
TG
BAS
BASF
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten